Clinical trial · Observational
Vincristine-induced Peripheral Neuropathy in Adult Survivors of Childhood and Adolescent Leukemia
Long-term Evaluation of Vincristine-induced Peripheral Neuropathy in Adult Survivors of a Multicenter Prospective Cohort of Childhood and Adolescent Leukemia (LEA Cohort): a Multicenter Cross-sectional Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Vincristine is a major anticancer agent in the management of hematological malignancies. One of the main side effects is chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a characteristic side effect of neurotoxic anticancer drugs. CIPN associated with vincristine is typically characterized by distal and symmetrical sensory symptoms (dysesthesia and paresthesia). Motor and vegetative symptoms can also be found. The prevalence of CIPN associated with vincristine during treatment ranges from 12 to 100% in children (depending on the endpoint). The aim of this cross-sectionnal study will be to explore the CIPN prevalence and severity in adult survivors of childhood leukemia and having been treated by vincristine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy-induced Peripheral Neuropathy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| self-administered questionnaire | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cohort of adult survivors having been treated by vincristine
- description
- Cohort of adult survivors having been treated by vincristine for a childhood leukemia
- interventionNames
- Behavioral: self-administered questionnaire
Primary outcomes (1)
- measure
- Sensitive chemotherapy-induced peripheral neuropathy
- timeFrame
- day 1
- description
- Scores of the sensitive subscale of the QLQ-CIPN20 questionnaire (quality of life questionnaire - chemotherapy-induced peripheral neuropathy 20 questions) scores : 0 least - 100 worst
Secondary outcomes (16)
- measure
- Motor chemotherapy-induced peripheral neuropathy
- timeFrame
- day 1
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: \- adult patient (\> 18-year) who received a vincristine-based chemotherapy for hematological malignancy in childhood Exclusion Criteria: * Secondary cancer (leukemia and/or cancer) * Active oncological pathology * Current cancer treatment * Adults protected
References
Publications (0)
Data not yet available